Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan Pharma Reports Positive Results for Gastric Cancer Treatment

publication date: May 28, 2013
Aslan Pharmaceuticals Pte reported that ASLAN001 was effective in a Phase II trial among heavily pre-treated gastric cancer patients. ASLAN001, a small-molecule pan-HER inhibitor, reduced cell proliferation and cell survival in gastric tumors that either coexpressed EGFR and HER2 or were HER2 amplified. Aslan, a Singapore based biopharma that in-licenses clinicial-stage assets, acquired global rights to the drug from Array BioPharma in 2011. More details....

Stock Symbol: (NSDQ: ARRY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital